← Back to Search

Telehealth Advance Care Planning for Myeloid Leukemia (TeleSICP Trial)

N/A
Recruiting
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up throughout the study, up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will assess if a telehealth-delivered program helps older patients with blood cancers communicate better with healthcare providers, reduce anxiety/distress, & complete advance directives.

Who is the study for?
This trial is for individuals aged 60 or older with certain blood disorders, including acute myeloid leukemia and myelodysplastic syndrome. Participants must be receiving outpatient care, able to give informed consent, and speak English.
What is being tested?
The study is testing a telehealth program designed to improve healthcare communication and reduce patient anxiety. It also aims to increase the completion of advance directives like MOLST (medical orders for life-sustaining treatment) forms.
What are the potential side effects?
Since this trial involves an educational intervention rather than medication, traditional physical side effects are not expected. However, discussing serious illness may cause emotional discomfort.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~throughout the study, up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout the study, up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Healthcare Communication: Health Care Climate Questionnaire
Secondary study objectives
Anxiety Symptoms: Generalized Anxiety Disorder-7 (GAD-7)
Completion of advance directives
Distress: Distress Thermometer

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Telehealth Serious Illness Care ProgramExperimental Treatment1 Intervention
The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).
Group II: ControlExperimental Treatment1 Intervention
Education materials developed by the NCI on "Communication in Cancer Care (PDQ®) - Patient Version"

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor
868 Previous Clinical Trials
548,915 Total Patients Enrolled

Media Library

Telehealth Serious Illness Care Program Clinical Trial Eligibility Overview. Trial Name: NCT05875805 — N/A
Myelodysplastic Syndrome Research Study Groups: Control, Telehealth Serious Illness Care Program
Myelodysplastic Syndrome Clinical Trial 2023: Telehealth Serious Illness Care Program Highlights & Side Effects. Trial Name: NCT05875805 — N/A
Telehealth Serious Illness Care Program 2023 Treatment Timeline for Medical Study. Trial Name: NCT05875805 — N/A
~129 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top